Autonomix Medical, Inc. announced on March 14, 2025, the successful completion of the integration and design enhancements of the Apex 6 Generator into its fully integrated transvascular treatment platform, now rebranded as the Autonomix Sensing and RF Ablation System. This milestone is crucial for advancing the company's technology.
The Apex 6 Generator, an existing FDA-cleared technology, was licensed from RF Innovations, Inc. in July 2024. Its integration provides a de-risked and cost-effective approach to accelerating the development of Autonomix's platform, aligning with the required RF generator specifications.
This achievement keeps the company on track for submitting its Investigational Device Exemption (IDE) application with the U.S. FDA and potentially initiating clinical trials in the United States in 2025. The goal is to support a labeling indication for commercializing the system as a treatment for pancreatic cancer pain.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.